EuroBiotech Report—Sanofi buys into AZ RSV asset and posts data, Nonprofit founds biotech, Bioversys and Horizon


Welcome to the latest edition of our weekly EuroBiotech Report. We start with two stories about Sanofi, which got the week going by paying €120 million ($126 million) upfront and committing to up to €495 million more for a piece of AstraZeneca’s respiratory syncytial virus monoclonal antibody. Sanofi then followed up with fresh data on its Regeneron-partnered atopic dermatitis drug dupilumab, which impressed once again in the weeks before its PDUFA date. Nonprofit Parkinson’s UK joined with the University of Sheffield to create a single-asset virtual biotech. Bioversys tapped Aptuit to support its hunt for novel targets and drugs against Gram-negative bacteria. Horizon Discovery bought the right to evaluate Amplycell’s cell line optimization technology. And more.—Nick Taylor

1. Sanofi pays €120M to buy into AstraZeneca RSV program

Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs and profits for a phase 2b asset with the potential to immunize infants against a virus that kills 160,000 children a year.

2. Sanofi, Regeneron post more positive dupilumab data

Sanofi and Regeneron have taken a deeper dive into phase 3 data on hotly tipped atopic dermatitis drug dupilumab. The fresh results further burnish the credentials of an asset that is up for review at FDA this month.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

3. Parkinson’s nonprofit founds virtual single-asset biotech

Nonprofit Parkinson’s UK has teamed up with the University of Sheffield to create a virtual biotech. The single-asset startup will work with service providers to advance an Nrf2 inhibitor toward the clinic.

4. Bioversys, Aptuit team up to find novel antibiotic targets

Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria. GlaxoSmithKline collaborator Bioversys is looking to Aptuit for drug discovery capabilities to support its own approach to overcoming antibiotic resistance.

5. Horizon taps Amplycell for cell line optimization tech

Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell. The agreement will see Horizon pay an undisclosed upfront fee to evaluate the effect of the Amplycell technology on its glutamine synthetase (GS) null CHO K1 cell line.

And more articles of note>>

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.